RecruitingNCT07573176
Seltorexant compared with placebo for depression in adults
About this title
Read the official source — NCT07573176This study evaluates the safety and effectiveness of Seltorexant for people with depression.
Medication studyAges 18–74Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Seltorexant for people with depression.
Who could participate?
Listed age limits: 18 years to 74 years.
- Listed locations
- Bryant and 44 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 30, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 600
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Argentina, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT07573176
- Official title
Show the full official title
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With Seltorexant
Recruitment & locations
RecruitingBryant, United States · Bellflower, United States · Glendale, United States
43 more locations
- Oceanside, United States
- Orange, United States
- Riverside, United States
- Walnut Creek, United States
- Doral, United States
- Hialeah, United States
- Maitland, United States
- Miami, United States
- Tampa, United States
- West Palm Beach, United States
- Atlanta, United States
- Snellville, United States
- Chicago, United States
- Baltimore, United States
- Boston, United States
- Watertown, United States
- Brooklyn, United States
- Las Vegas, United States
- Marlton, United States
- Mount Kisco, United States
- New York, United States
- Cary, United States
- Cincinnati, United States
- Edmond, United States
- Philadelphia, United States
- Dallas, United States
- Houston, United States
- Oklahoma, United States
- Stafford, United States
- Clinton, United States
- Bellevue, United States
- Córdoba, Argentina
- Mendoza, Argentina
- Salvador, Brazil
- São Bernardo do Campo, Brazil
- São Paulo, Brazil
- North Vancouver, Canada
- Kingston, Canada
- Beijing, China
- Shanghai, China
- Kuala Lumpur, Malaysia
- Taichung, Taiwan
- Taipei, Taiwan
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Seltorexant for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Does this study involve medication?
Yes. The study involves medication, including Seltorexant and Placebo.
Who can participate?
Listed age limits: 18 years to 74 years.
Is this study still recruiting?
The registry lists this study as recruiting.
